Document is current
Any future updates will be listed below
-
Authors
Kim, Ji Won
Nam, Soo Hyun
Lee, Geon Seong
Chung, Hye Yoon
Kim, Eun Young
Han, Jeong Pil
Jang, Jae-Hyung
Choi, Byung-Ok
Yeom, Su Cheong
-
Funding
Funding for this research was provided by:
Korean Health Technology R&D Project, Ministry of Health & Welfare (HR22C1363, RS-2024-00438444)
the Regenerative Medicine co-funded by Ministry of Science and ICT and Ministry of Health and Welfare (23C0115L1)
Future Medicine 2030 Project of the Samsung Medical Center (SMO1240041)
Korean National Research Foundation (RS-2025-00515382)
Seoul National University
- License Information
-
More Information
Article History
Received: 15 April 2025
Revised: 26 July 2025
Accepted: 29 July 2025
First Online: 4 August 2025
Declarations
:
: GSL, BOC and SCY filed a provisional patent based on this work.
: All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Seoul National University (Approval No. SNU-241108–6). This study involved members of a family harboring MORC2 variants, including two clinically affected individuals. Written informed consent was obtained from all participants prior to enrollment. The study protocol was approved by the Institutional Review Board of Samsung Medical Center, Sungkyunkwan University (IRB No. 2014–08-057–002).
: All authors have read the final version of the manuscript and approved it for publication.
